What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce and provide access to an investor presentation that AbbVie Inc. posted on its website on January 10, 2023. This ensures that material information is disseminated to the public in accordance with Regulation FD.

Where can I find the details of the investor presentation mentioned in the filing?

The investor presentation is attached as Exhibit 99.1 to this Form 8-K. Investors can access this exhibit through the SEC's EDGAR database or directly via AbbVie's investor relations website.

Does this 8-K filing contain new financial results or operational guidance?

No, this specific 8-K filing does not contain new financial statements or detailed operational guidance. Its purpose is to disclose the availability of the investor presentation, which is where such information is likely to be found.

Is the information in the investor presentation considered 'filed' with the SEC?

According to the filing, the information in Item 7.01 and Exhibit 99.1 is furnished and not 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means it's not automatically incorporated into previous or future SEC filings unless specifically referenced.

ABBV 8-K: Regulation FD

Summary

AbbVie Inc. (ABBV) filed an 8-K on January 10, 2023, primarily to disclose the posting of an investor presentation to its website. This presentation, dated January 10, 2023, is attached as Exhibit 99.1 to the filing. While the 8-K itself does not contain new operational or financial data, it serves as the official channel for investors to access this supplementary presentation. Investors should refer to Exhibit 99.1 for details on AbbVie's strategic outlook, business updates, and financial performance, as this presentation is likely to contain the most current insights from management.

Key Highlights

1AbbVie Inc. filed an 8-K on January 10, 2023, to publicly share an investor presentation.
2The investor presentation is dated January 10, 2023, and is attached as Exhibit 99.1.
3The filing is a Regulation FD disclosure, ensuring broad public access to the information.
4The content of the investor presentation is not considered 'filed' for purposes of Section 18 of the Securities Exchange Act, but is considered furnished.
5This 8-K indicates that investors should look to the provided presentation for key updates and strategic information.
6The Chief Financial Officer, Scott T. Reents, signed the report.

AbbVie Inc. 8-K Report, Regulation FD Disclosure (Jan 10, 2023)

Summary

Key Highlights

Frequently Asked Questions